Glenmark Pharma's board approved selling a 7.84% stake in Glenmark Life Sciences through an OFS to raise funds for growth.
Glenmark Pharma's board approved selling a 7.84% stake, equivalent to 96,09,571 equity shares, in Glenmark Life Sciences. The stake will be sold through stock exchanges using an offer for sale (OFS). The sale aims to raise funds and is expected to contribute to Glenmark Pharma's growth strategies.
July 10, 2024
3 Articles